Unbiased AI-powered news
@statnews reported that ADA leaders prevented Diabetes Care editors from publishing an editorial and accounts about five specialists ejected from the group's June meeting in New Orleans. The pieces remain available on an open-access site.
prnewswire.comLeaders of the American Diabetes Association blocked editors at its flagship journal Diabetes Care from publishing an opinion piece and first-person accounts about a controversy at the group's annual meeting, @statnews reported on July 16, 2026. The controversy centered on five diabetes specialists who were escorted out of a conference center in New Orleans in early June for handing out reprints of an editorial that expressed concern over cuts to federal research.
The incident occurred nearly five weeks before the July 16 report.
The ADA apologized for the evictions and pledged a formal review. It delayed publication of the editorial and accounts pending the outcome of that review. The spiked editorial and personal accounts are available on an open-access website.
In those pieces the ejected specialists detail their treatment. Prominent ADA members, including past leaders and one who resigned after the confrontation, express dismay over how the events were handled. All voice disappointment over the decision to suppress views opposing policies of the Trump administration.
They also disagree with how ADA leadership handled the episode and its aftermath.
Single source — no framing comparison available.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
washingtonpost.comFlooding along the Guadalupe River has killed at least one person in central Texas. The same area recorded more than 130 deaths in flash floods last summer. Governor Greg Abbott confirmed the fatality in a Thursday update.
dailywire.comKalshi will allow bets on selected clinical trial results and full FDA decisions, starting with Phase 3 studies from established companies. The FDA separately approved Merck's Lipfendra cholesterol pill based on studies showing up to 60% LDL reduction.